Meeting scheduled for insulin degludec and insulin degludec/insulin aspart
18 July 2012 | By Novo Nordisk
Meeting scheduled to discuss the NDA for the ultra-long-acting insulin degludec & insulin degludec/insulin aspart....
List view / Grid view
18 July 2012 | By Novo Nordisk
Meeting scheduled to discuss the NDA for the ultra-long-acting insulin degludec & insulin degludec/insulin aspart....
17 July 2012 | By Merck
Five Inaugural Fellows Will Use Skills and Talents to Help Enhance Quality and Scalability of PSI’s Country Operations...
17 July 2012 | By GlaxoSmithKline
Fabry products to be commercialised by Amicus in US and by GSK ex-US...
17 July 2012 | By Biogen Idec
Labs at Duke University and HudsonAlpha Institute to lead research consortium...
16 July 2012 | By GlaxoSmithKline
GSK to acquire full ownership of BENLYSTA®, albiglutide and darapladib...
16 July 2012 | By AstraZeneca
AstraZeneca reported on the remuneration arrangements relating to David Brennan’s retirement...
16 July 2012 | By GlaxoSmithKline
GSK launches new advertising campaign...
16 July 2012 | By Gilead Sciences
The U.S. FDA has approved once-daily oral Truvada®...
16 July 2012 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Ilka Diester...
16 July 2012 | By Abbott
The Abbott Fund announces $1 million partnership...
13 July 2012 | By Merck
Merck announced presentations at the upcoming AAI Conference...
Abbott will feature new solutions to improve data management and automation at this year’s American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today’s laboratories will be the focal point of the Abbott exhibit.
13 July 2012 | By GlaxoSmithKline
Relvar™ and Breo™ proposed as brand names for FF/VI in EU and US...
12 July 2012 | By Daiichi Sankyo
Daiichi Sankyo has been approved for the Japanese Ministry of Economy, Trade and Industry’s production facility building grant...
12 July 2012 | By GlaxoSmithKline
GlaxoSmithKline has withdrawn a supplemental New Drug Application to the US FDA for Tykerb...